Drugs

Join me at my 100th birthday party in 2049!

We speak with GRG's Johnny Adams, a key contributor to the Longevity2020 online conference, about his quest for more healthy years. One of the speakers at this month’s...

Low-dose rapamycin to protect elderly from COVID-19

Longevity researcher proposes clinical trials for low-dose rapamycin (and other geroprotectors) to protect the elderly from COVID-19. The UK's Biogerontology Research Foundation today announced the...

Early intervention and disease prevention = Longevity

Talking prevention and treatments for Longevity with Prodrome's Dayan Goodenowe. Detecting prodromes – an early indication of a developing condition or disease – could revolutionise...

Chemical screening to find hidden Longevity gems?

Start-up NemaLife evolves from platform technology to services provider to identify chemicals that have both positive and negative effects on Longevity. The use of the...

From machines to animals to humans

Exclusive with Prof Joao Pedro de Magalhaes: talking AI, indication expansion and animal models. “Will you still need me, will you still feed me, when...

Some good news: announcing Longevity2020

In these challenging times, with everyone working from home and conferences pushed-back to later this year, we had an idea: Longevity2020 While the world overcomes...

FDA clears the way for AgeX’s pluripotent stem cell tech

FDA announces that ImStem drug IMS001 that uses AgeX's pluripotent stem cell technology will be available for treatment of multiple sclerosis. IMS001 was derived from the pluripotential...

Nutraceuticals to beat cognitive decline before it starts

Talking nutraceuticals and pharmaceuticals, trials, scaling-up and Singapore with the founder of Senescence Life Sciences. Singapore-based Senescence Life Sciences aims to use nutraceuticals to combat natural brain...

Metabolic aging, fasting and metformin

The presence of a “metabolic clock” that regulates aging involves the accumulation of metabolic alterations and a decline in metabolic homeostasis and biological fitness. An...

The Reason behind Longevity: start-up opportunities

We connected with Reason (the person) to get the inside track on hot areas for Longevity R&D.   Longevity.Technology: Advocacy runs through Reason like a...

Cerevance raising $60m for brain disease drug discovery

Company awaits Phase 2 trial readout for new Parkinson’s drug as part of its mission to combat brain disease. In the world of Longevity start-ups,...

Proving the Longevity potential of NAD+

Talking sirtuins, NAD+ and trials with Elysium Health CEO Eric Marcotulli. When it comes to the world of consumer anti-aging supplements, there are few higher-profile...

LSD = Longevity (and) stalled dementia?

New York-based biotech company Eleusis has completed a phase 1 trial of the psychedelic drug LSD and is moving forward to phase 2. Could...

Fishing for regenerative therapies

Talking Longevity, indication expansion, killifish and regeneration with Dr Aric Rogers from the MDI Biological Laboratory. Nestled on the picturesque coastline of Maine, USA, the...

EnClear bags $10m to start first in-human

We talk exclusively with the Longevity start-up targeting neurodegenerative disease with novel therapeutic filtration (device) technology. Its mission: access and control cerebrospinal fluid to get...

J&J enters Longevity market with “Immorbidity” play

A new competition aims to find the next great breakthrough to help us stay active and healthy beyond the age of 100. People are living...

Rejuvant shows positive early results in humans

Anecdotal results for dietary supplement show significant improvements in biological age and major reductions in key blood biomarkers. In our recent interview with leading Longevity...

Indication expansion to meet Longevity market demand

Several compounds have demonstrated life-extending effects in animal models, some of which are currently being tested for their ability to exert anti-aging effects in...

Alkahest Parkinson’s clinical trial gets funding boost

Alkahest announced today that they have initiated a phase 2 clinical trial with funding from the Michael J. Fox Foundation (MJFF). Today's press release reveals...

“Human-on-a-Chip” OOC to revolutionise preclinical

New system of linked mini-organs heralds a new era of comprehensive drug testing that is faster and more efficient than anything seen before. OOC...

Latest articles

COVID-19: Leading clinician calls for focus on the biology of aging

Dr Nir Barzilai predicts that rapamycin could decrease severity of coronavirus in the elderly by 50%. When it comes to the world of Longevity and...

Global investment consortium slated to back Telocyte into Phase 1

Telomerase therapy ready for human Alzheimer’s trials. “There have been more than 400 registered trials for Alzheimer's and, by global consensus, every single one has...

Longevity 2020: shaping-up nicely

Over 45 confirmed speakers for this 5-day online event and a big thank you for your interest. We're moving fast! Longevity 2020 started just over...

Telomeres on repeat to inhibit inflamm-aging

Coming around again – Italian team hopes to use repeated nucleobases to delay aging through extending telomeres. Inflammation is a double-edged sword; while it is necessary...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.